Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Ticagrelor vs Double-dose Clopidogrel in Clopidogrel-Resistant CHD
NCT03614832Phase 4
Key facts
- Status
- Unknown
- Start
- May 2018
- Primary completion
- May 2019
- Countries
- 1
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Modality
- Small Molecules
- Drugs
- ticagrelor
- Conditions
- coronary heart disease (CHD)
01
Overview
Phase 4, randomised, open-label trial of ticagrelor in coronary heart disease (CHD) (2 arms), sponsored by The First Affiliated Hospital of Harbin Medical University. Primary endpoint: The platelet inhibition ratio at 7 days. Status: unknown.
02
Design
2 arms- Study design
- RandomizedOpen-label
Ticagrelor 90 mg
Ticagrelor 90 mg loading dose, then 90 mg once daily
Clopidogrel 150 mg
Clopidogrel 150 mg loading dose, then 150 mg once daily
03
Who it enrols
Patients with coronary heart disease and high on-treatment platelet reactivity (HTPR) while on clopidogrel.
04
Endpoints
Primary
The platelet inhibition ratio
Secondary
The platelet aggregation ratio
Beyond the preview
Go deeper on NCT03614832.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03614832.